Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
16.47
+0.53 (3.29%)
Dec 3, 2024, 2:04 PM EST - Market open
Arcus Biosciences Employees
Arcus Biosciences had 577 employees as of December 31, 2023. The number of employees increased by 77 or 15.40% compared to the previous year.
Employees
577
Change (1Y)
77
Growth (1Y)
15.40%
Revenue / Employee
$455,806
Profits / Employee
-$467,938
Market Cap
1.50B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Evolent Health | 4,700 |
Novavax | 1,543 |
Indivior | 1,164 |
STAAR Surgical Company | 1,057 |
Alphatec Holdings | 839 |
Maravai LifeSciences Holdings | 650 |
Bicycle Therapeutics | 284 |
Syndax Pharmaceuticals | 184 |
RCUS News
- 13 days ago - Arcus Biosciences to Participate in Two Upcoming Investor Conferences - Business Wire
- 20 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 26 days ago - Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 26 days ago - Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update - Business Wire
- 4 weeks ago - Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer - Business Wire
- 4 weeks ago - Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting - Business Wire
- 5 weeks ago - First Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer - Business Wire
- 5 weeks ago - Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update - Business Wire